Skip to main content
CLDX
NASDAQ Life Sciences

巴索利单抗显示出持续的疗效和疾病修饰作用，在2期荨麻疹数据中

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$29.545
Mkt Cap
$1.967B
52W Low
$14.4
52W High
$31.31
Market data snapshot near publication time

summarizeSummary

Celldex Therapeutics 在2026年AAAI会议上展示了其领先资产巴索利单抗在慢性自发性荨麻疹（CSU）、冷性荨麻疹（ColdU）和症状性皮肤图形症（SD）中的额外阳性2期数据。数据突出了CSU患者在停止治疗后的持续疗效，其中最多有41%的患者在最后一次剂量后七个月内实现了完全缓解，表明了潜在的疾病修饰作用。这是一个重要的发现，因为它意味着治疗结束后仍然具有持久的影响。这一积极的更新是在公司最近宣布在CSU中完成巴索利单抗3期招募的背景下，如最近的10-K文件中所述。新的数据进一步加强了巴索利单抗作为潜在的'第一类和最佳治疗'的特征，大大降低了资产风险并提高了其商业前景。投资者现在将密切关注正在进行的3期CSU试验的进展和最终结果。

在该公告发布时，CLDX的交易价格为$29.55，交易所为NASDAQ，所属行业为Life Sciences，市值约为$19.7亿。 52周交易区间为$14.40至$31.31。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CLDX - Latest Insights

CLDX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Celldex Seeks Shareholder Approval for 3.4M Share Increase in Equity Incentive Plan
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 06, 2026, 10:53 AM EDT
Source: GlobeNewswire
Importance Score:
7
Celldex Therapeutics Secures $345M from Public Offering, Underwriters Fully Exercise Option
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
Celldex Therapeutics Prices $300M Public Offering to Fund Barzolvolimab Commercialization and Pipeline
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Celldex Therapeutics Prices $300 Million Public Offering, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
CLDX
Apr 01, 2026, 9:48 PM EDT
Source: Reuters
Importance Score:
8
$300 Million Stock Offering Priced by Celldex at $29.00 Per Share
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 01, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex Proposes Public Stock Offering to Fund Barzolvolimab Commercialization
Sentiment: Negative
View Wiseek Article
CLDX
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex's Barzolvolimab Shows Profound, Durable Quality of Life Improvements in Phase 2 Urticaria Studies
Sentiment: Positive
View Wiseek Article
CLDX
Mar 01, 2026, 9:45 AM EST
Source: GlobeNewswire
Importance Score:
8
Barzolvolimab Retreatment Shows Profound Efficacy in Cold Urticaria and SD, Reinforcing Best-in-Class Profile
Sentiment: Positive
View Wiseek Article
CLDX
Feb 27, 2026, 2:45 PM EST
Source: GlobeNewswire
Importance Score:
9
Barzolvolimab Shows Sustained Efficacy, Disease Modification in Phase 2 Urticaria Data
Sentiment: Positive
View Wiseek Article
CLDX
Feb 25, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Celldex Therapeutics Advances Multiple Clinical Programs, Secures Liquidity Through 2027
Sentiment: Positive
View Wiseek Article